Helping you detect, treat and manage arthritis

SPINACH 2-project: SupPortIng seNiors And Caregivers to stay mobile at Home

SPINACH 2-project: SupPortIng seNiors And Caregivers to stay mobile at Home

Participants sought for interview/focus group about online module with options on how to stay independent at home when aging

A picture of seniors in a fieldDecisions about how to stay independent at home are difficult ones for seniors, and we often hear that they do not know what their options are to do so.

We have created an online module (webpage) for seniors and caregivers who are facing decisions (with their health professionals) about how to stay independent at home which could be optimized with your feedback!

Continue reading

You’re invited! Free 2017 Calgary Ankylosing Spondylitis & Psoriatic Arthritis Public Information Forum

AS and PsA Forum BannerJoin guest speakers for a free information session to learn more about ankylosing spondylitis and psoriatic arthritis and how to effectively manage these conditions.

Date: Saturday, November 18, 2017
Time: 8:30 am-12:30 pm
Speaker presentations start at 9:00 am

Location:
WINSPORT Multi-purpose Room
88 Canada Olympic Road SW
Calgary, Alberta, T3B 5R5

To register online, please click here or email execdirector@spondylitis.ca or phone (705) 715-2162. On-site registration opens at 8:30 am. Refreshments will be served.

The following topics will be discussed:
Disease overview & diagnosis
Treatment options
What’s new and on the horizon
Pain management
Non-pharmacologic treatment

Guest speakers:
Dr. Diane Mosher (Rheumatologist)
Dr. Olga Zouzina (Rheumatologist)
Carolyn Johns (Physiotherapist)
Alex Charlton (pharmacist)
Patient Speaker

Call for patient input on tocilizumab (Actemra®) for giant cell arteritis

Stickman with megaphone calling for patient inputCall for patient input on tocilizumab (Actemra®) for giant cell arteritis

Do you have giant cell arteritis? We need your valuable input.

The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for tocilizumab (Actemra®) for the treatment of giant cell arteritis.

The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec).

To help them make their recommendations, the CDR accepts input from patient organizations and groups, like Arthritis Consumer Experts (ACE). Because patient input is vitally important to government decision-making about medications, we would like to gather your views and share them with the CDR.

These are the questions they are asking: Continue reading

Do you have rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis or plaque psoriasis?

Stickman with megaphone calling for patient inputCall for patient input on biosimilar infliximab (Merck) for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis

Do you have rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis or plaque psoriasis? We need your valuable input

Health Canada defines biosimilars as biologic medicines that are similar to, and would enter the market after, an approved originator biologic (such as Remicade®).

The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for biosimilar infliximab for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis. The originator biologic, or reference product, is infliximab (Remicade®).

The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec).

To help them make their recommendations, the CDR accepts input from patient organizations and groups, like Arthritis Consumer Experts (ACE). Because patient input is vitally important to government decision-making about medications, we would like to gather your views and share them with the CDR.

These are the questions they are asking: Continue reading

Let BC PharmaCare hear “Your Voice” on biosimilar etanercept

Stickman with megaphone calling for patient inputBC PharmaCare is looking for your input on biosimilar etanercept (Erelzi) for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis and rheumatoid arthritis

Biosimilar etanercept (Erelzi) is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide your input on biosimilar etanercept for the treatment of ankylosing spondylitis (AS), juvenile idiopathic arthritis (JIA) and rheumatoid arthritis (RA). You can give input if you are a B.C. resident and have AS, JIA or RA, a caregiver to someone with AS, JIA or RA, or if your group represents people who live with AS, JIA or RA.
Continue reading

Throwback Lupus – What was the state of lupus in 2010?

Slide image with butterfly to represent lupusIn honour of Lupus Awareness Month, the Arthritis Broadcast Network is doing a throwback coverage on lupus. The coverage highlights Arthritis Research Canada and Arthritis Consumer Experts’ coverage of the 9th International Congress on Systemic Lupus Erythematous, Vancouver 2010 (“Lupus 2010”). The event was held in Vancouver, British Columbia, Canada in June, 2010. Hundreds of world leading researchers, healthcare professionals, and individuals living with systemic lupus erythematosus (SLE) learned about the current state of the science in SLE and future opportunities in lupus research, education and care.

The objectives of the Lupus 2010 were to: Continue reading

Canadian Obesity Network publishes first-ever Report Card On Access to Obesity Treatment

Canadian Obesity Network publishes first-ever Report Card On Access to Obesity Treatment For Adults in Canada 2017

A paradigm shift in the prevention and treatment of obesity.

Report Card on Obesity Treatment Cover PhotoThe report is a shift away from considering obesity to be merely the result of poor lifestyle choices toward a socio-ecological model of health that carries with it an obligation to our health systems and society to prevent and treat it as we do other chronic diseases.

Understanding your Body Mass Index (BMI)
Health Canada’s Canadian Guidelines for Body Weight Classification in Adults uses the Body Mass Index (BMI) to determine if someone is overweight. You can calculate your BMI using the formula below or online here:

BMI = weight (kg)/height (m)2

Health Canada’s Health Risk Classification According to Body Mass Index (BMI) table shows the correlation between your BMI score and your risk of developing health problems, such as type 2 diabetes, high blood pressure, heart disease, stroke, arthritis and cancer. Please note other factors may influence your BMI. You should consult your family physician if you are concerned about being overweight.
Continue reading

It’s not your fault you are depressed…YOU are not making your RA worse

Woman with text It's not your fault you are depressedPeople living with rheumatoid arthritis (RA) are twice as likely as the rest of the population to feel depressed. An important thing to understand is that it is NOT your fault you are depressed, therefore, YOU are not making your RA worse. It is natural to feel anxious or sad as a result of the diagnosis and to be depressed as a symptom of the disease. Instead, realise that it just demonstrates that rheumatoid arthritis is a complex condition that may require multiple levels of treatment; and, that an important strategy for reducing the pain of arthritis is treating your depression. Two approaches can be used, non-pharmacological and pharmacological, together or individually.

Separate from improving mood, antidepressants have been shown to reduce pain in many different chronic conditions, including arthritis, and they work even when depression is not a factor. How these drugs work to reduce pain is not fully understood, but may have to do with improving sleep, relaxing muscles, or increasing neurotransmitters in the spinal cord that are responsible for lessening pain signals.

Please consult your doctor to discuss your treatment options.

There are many strategies you can try, which you may find useful for helping you to avoid or alleviate depression without using drugs. No matter what suggestions you decide will work best for you, we recommend you speak with your doctor or therapist before getting started: Continue reading

Do it for the kids! Juvenile arthritis: Exercise, models of care, and advocacy

Four kids playing at the park

In honour of Juvenile Arthritis Awareness Month in Canada, we have compiled a list of interviews from this year’s CRA Annual Scientific Meeting & AHPA Annual Meeting in Ottawa. The interviews below highlight models of care, advocacy, clinical practices, and different therapy options for juvenile arthritis.  Continue reading

JointHealth™ insight – March 2017: Arthritis in the workplace

JointHealth™ insight – March 2017

Arthritis in the workplace: Are employers and employees speaking the same language? 

Arthritis in the workplace - two human cartoon talkingIn this issue of JointHealth™ insight, Arthritis Consumer Experts looks at the current state of arthritis in the workplace. Find out what makes the City of Ottawa and Aboriginal Peoples Television Network two of Canada’s best workplaces for employees living with arthritis.

In this issue, you will also find:

  • A summary on arthritis in the workplace, including the latest statistics about the cost of work disability
  • Suggestions on what kind of flexible work arragements would help workers with arthritis
  • Key messages for employers
  • Tips for employees living with arthritis